Summary

Results from the 3T/2R study [NCT00398463] demonstrated that the addition of tirofiban to standard therapy decreased the rate of myocardial infarction and resulted in a lower rate of major cardiovascular events 30 days after percutaneous coronary intervention compared with standard antiplatelet therapy alone in poor responders to aspirin or clopidogrel.